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ABSTRACT We designed a universal human papillomavirus (HPV) typing assay based
on target enrichment and whole-genome sequencing (eWGS). The RNA bait included
23,941 probes targeting 191 HPV types and 12 probes targeting beta-globin as a
control. We used the Agilent SureSelect XT2 protocol for library preparation, Illumina
HiSeq 2500 for sequencing, and CLC Genomics Workbench for sequence analysis.
Mapping stringency for type assignment was determined based on 8 (6 HPV-positive
and 2 HPV-negative) control samples. Using the optimal mapping conditions, types
were assigned to 24 blinded samples. eWGS results were 100% concordant with Lin-
ear Array (LA) genotyping results for 9 plasmid samples and fully or partially concor-
dant for 9 of the 15 cervical-vaginal samples, with 95.83% overall type-specific con-
cordance for LA genotyping. eWGS identified 7 HPV types not included in the LA
genotyping. Since this method does not involve degenerate primers targeting HPV
genomic regions, PCR bias in genotype detection is minimized. With further refine-
ments aimed at reducing cost and increasing throughput, this first application of
eWGS for universal HPV typing could be a useful method to elucidate HPV epidemi-
ology.
KEYWORDS HPV typing, broad-spectrum assay, whole-genome sequencing, target
enrichment
Human papillomaviruses (HPV) are double-stranded DNA viruses in the familyPapillomaviridae. More than 200 genotypes are recognized based on the sequence
of the approximately 8-kbp circular genome, with variants in each genotype based on
sequence relatedness (1, 2). Detection and typing of HPV has clinical and public health
significance because of the association of some genotypes in the Alphapapillomavirus
genus with anogenital and oropharyngeal cancers. As a result, most assays used in HPV
epidemiology and natural history studies are directed to these genotypes, and many
PCR-based assays use degenerate primers directed to the L1 region of the HPV genome
(3, 4). Studies examining disease associations of an increasingly broad spectrum of HPV
genotypes have been hampered by the need for multiple assays to detect genotypes
in alpha, beta, and gamma genera (5, 6).
Next-generation sequencing (NGS)-based methods have the promise to improve the
spectrum of HPV genotypes detected. Some NGS methods used PCR with consensus
primers targeting the L1 region for library preparation, restricting regions of the
genome that could be analyzed (7–13). HPV genome sequencing to single or limited
HPV genotypes was achieved using the standard protocol for library preparation
without any target enrichment (14) or after whole-genome amplification by rolling-
circle amplification (15) or highly multiplexed degenerate primers (16). There are a few
reports of NGS using target enrichment to study the mechanistic signatures of inte-
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gration of a limited number of HPV genotypes in cervical carcinomas (17–19). The goal
of this study was to capitalize on the availability of new target enrichment technology
to facilitate whole-genome sequencing to detect, genotype, and potentially character-
ize variant and integration statuses of all known HPVs belonging to alpha, beta, and
gamma genera using a single assay. Target enrichment technology uses hybridization
to purify genomic fragments of interest with DNA or RNA baits. DNA/RNA baits were
initially used and proved to be highly effective to enrich human exomes for variant
calling by deep sequencing (20, 21). We developed custom RNA baits specific to all
known HPV genomes to enrich the sample for sequencing of whole viral genomes.
Here, we describe and provide an initial evaluation of this whole-genome sequence-
based approach for broad-spectrum HPV genotype determination in samples with
single and multiple HPV infection using the Agilent SureSelect target enrichment
technology.
RESULTS
Assessment of sequence data quality. DNA sheared to approximately 150 bp is
expected to increase in size to around 300 bp in the indexed library after ligation of
adaptors that enable limited PCR amplification and sequencing of the library. As
expected, bioanalyzer analysis of the indexed pooled libraries prepared for sequencing
indicated the size distribution with a peak around 300 bp. The seed concentration of 5.3
pM generated cluster densities of 1,173,000 and 1,183,000/mm2 in pool 1 (samples 1 to
16) and 2 (samples 17 to 32), respectively. All raw reads from both pools passed the
default filtering of the Illumina BCl2fastq V1.8.4 software (pool 1, 268,096,524; pool 2,
226,336,668). The average number of reads per sample in pool 1 was 8,538,564, and
that from Caski at 100 ng (sample 11) with 500 HPV16 copies/cell dominated,
comprising 21.9% of the total (Fig. 1A). The average number of reads per sample in pool
2 was 11,224,892. The mean base quality (Q) score for each sample (excluding sample
9, the water control) ranged from 34.57 to 36.87 (mean Q of 35.6), and 88% of the bases
had quality scores greater than 30 (Fig. 1B). The water control generated 3,692 reads
FIG 1 Number of reads (A) and mean base quality (Q) score of reads (B) passing the default filtering of
Illumina BCl12fastq V1.8.4 software. Reads were restricted to 0 mismatches in 8-bp index reads.
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with Q scores ranging from 2 to 40 (mean Q of 25), with only 47% of bases having a Q
score greater than 30.
Mapping results for internal control HBG. The fraction of the globin reference
sequence mapped in all samples with genomic DNA (all except the water control,
sample 9) ranged from 93 to 100% (mean, 98%). Samples with 100 ng genomic DNA
(samples 1 to 8, 10 to 11, 13, 15, and 17 to 32) generated a mean of 7,406 reads (range,
1,903 to 11,225) that, using L1-S1 stringency, mapped to the globin reference (human
beta-globin [HBG] nucleotides [nt] 2041 to 3480) with an average depth of coverage
ranging from 132.2 to 779.5 (mean coverage, 514.3) (Fig. 2). The number of mapped
reads (range, 902 to 3,327; mean, 2,000.3) and coverage (range, 62.6 to 231; mean,
138.9) were reduced in samples with 10 ng genomic DNA (samples 12, 14, and 16). Only
2 reads from the water control (sample 9) mapped to beta-globin (depth of coverage
of 0.1 and fraction of reference sequence mapped of 12%).
Evaluating cutoff to improve signal/noise ratio for HPV genotyping from
whole-genome sequence data. We evaluated mapping results for the 8 control
samples (Table 1) in terms of the number of reads, average coverage, and the fraction
of genome covered using different stringencies to differentiate signal from noise for
FIG 2 Performance of RNA baits for internal control human beta-globin gene based on number of reads
(A), average coverage (B), and fraction of reference sequence covered by the reads (C).
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determination of HPV genotype. Caski (100 ng) generated a total of 50,890,604 reads
mapped to any HPV reference sequence, of which 99.94% of reads (50,861,070 reads)
mapped specifically to HPV16 under the less stringent L0.5-S0.8 mapping condition.
Whole-genome sequencing (WGS) also detected HPV16 in SiHa (134,664 out of 164,138
total reads; 82.04%) cells and HPV18 in HeLa (314,969 out of 342,887 total reads;
91.86%) cells as the most dominant types. Without any cutoffs for nonspecific signal, all
positive controls detected additional HPV types under all three mapping stringencies.
The presence of nonspecific signal was also seen in water and placental DNA negative
controls. For example, WGS detected HPV16 with 1,800 reads in the negative placental
DNA using L0.5-S0.8. With increased mapping stringency (L1-S1), placental DNA still
detected HPV16 with 861 reads and average coverage of 10.9. Based on this, we
selected a cutoff of 1,000 mapped reads and average coverage of 20 for reliable
sequence assignment. We also added the fraction of reference genome covered of0.5
(to indicate that at least 50% of the viral genome is retained, allowing for loss due to
potential integration events) to the cutoff parameters. With L1-S1 mapping stringency
and the selected cutoffs (number of mapped reads of 1,000, average coverage of
20, and fraction of genome covered of 0.5), HPV genotyping results for the 8
controls were concordant with the expected results (Table 1). The control cell line
samples, Caski (500 HPV16 copies/cell), HeLa (50 HPV 18 copies/cell), and SiHa (1 to
2 HPV16 copies/cell), vary in known copy numbers of HPV and were analyzed at two
concentrations of input DNA (100 ng and 10 ng). In each case, the number of mapped
reads under stringent conditions roughly correlated with copy number (Table 1), and
type assignment could be made with input of 10 ng DNA. The fraction of genome
covered for HPV18 in the HeLa cell line was only 63%. No reads mapped to a 2.6-kbp
central region (nt 3100 to 5730), compatible with a deletion (Fig. 3).
Determination of HPV types from WGS data. Enriched whole-genome sequenc-
ing (eWGS) data from the remaining 24 samples were analyzed using criteria set in the
control samples to assign WGS HPV results without knowledge of prior HPV data.
Comparing eWGS typing results with prior Linear Array (LA) results, type-specific HPV
detection was at least partially concordant in 18 of 24 samples (75%) (Table 2).
Genotype determinations for the 9 HPV plasmids (HPV45, -58, -31, -33, -52, -6, -18, -11,
and -16) were 100% concordant. The average depth of coverage for the 9 WHO
plasmids ranged from 1,210 to 3,751 with a mean of 2,837. Among the 15 cervicova-
TABLE 1 Determination of cutoff to differentiate signal from noise in HPV whole-genome sequence data based on control samples
Control
sample
Mapping results for stringency conditiona:
HPV typeL0.5-S0.8 L0.5-S1 L1-S1
No. of reads
mapped
Avg
coverage
Fraction of
genome
covered
No. of reads
mapped
Avg
coverage
Fraction of
genome
covered
No. of reads
mapped
Avg
coverage
Fraction of
genome
covered
Without
cutoff
With
cutoffb
Caski (100 ng) 50,861,070 637,921.0 1.00 49,687,563 624,209.5 1.00 31,807,177 402,316.9 0.99 16 16
187 2.1 0.63 139 1.7 0.57 116 1.5 0.50 33
Caski (10 ng) 9,020,079 113,103.0 1.00 8,807,582 110,605.2 1.00 5,582,647 70,612.8 0.99 16 16
37 0.4 0.16 14 0.2 0.12 10 0.1 0.10 45
SiHa (100 ng) 134,664 1,679.0 1.00 130,955 1,638.0 1.00 87,797 1,110.5 0.98 16 16
75 0.9 0.22 65 0.8 0.19 47 0.6 0.12 18
SiHa (10 ng) 68,146 850.0 1.00 66,413 831.1 1.00 44,921 568.2 0.98 16 16
94 1.0 0.33 66 0.8 0.30 59 0.7 0.29 31
HeLa (100 ng) 314,969 3,953.7 0.67 298,994 3,760.7 0.67 183,032 2,329.5 0.64 18 18
1,339 16.0 1.00 1,100 13.8 1.00 659 8.3 0.90 16
HeLa (10 ng) 83,489 1,049.0 0.66 78,847 992.9 0.66 48,305 614.8 0.62 18 18
610 7.3 0.99 409 5.1 0.98 225 2.8 0.77 16
H2O 115 1.5 0.29 110 1.4 0.27 69 0.9 0.18 18 Negative
12 0.1 0.13 2 0.0 0.02 1 0.0 0.01 16
Placenta 1,800 21.3 1.00 1378 17.3 1.00 861 10.9 0.88 16 Negative
46 0.5 0.26 37 0.5 0.24 23 0.3 0.16 18
aThree mapping stringencies (L0.5-S0.8, L0.5-S1, and L1-S1) were evaluated using combination of parameters L and S, which represent read length (0.5 or 1) and
similarity score (0.8 or 1), respectively.
bHPV types were determined following cutoff on number of mapped reads of 1,000, average coverage of 20, and fraction of genome covered of 0.5 under L1-S1
mapping stringency.
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ginal swab samples, typing results for 9 samples were fully or partially concordant. Of
these 9, full concordance was found in 5 samples, 2 samples negative for HPV and 3
samples with multiple types (3, 4, and 8 types). Among the 6 discordant samples, 4
were negative by eWGS but positive for multiple types by LA, whereas 2 samples were
HPV positive by both methods but for different types. The overall type-specific con-
cordance for types included in the LA assay was 95.83%, and for LA-targeted types,
there were no instances of samples positive by eWGS and negative by LA. In six
samples, eWGS identified HPV types not included in the LA assay (HPV30, -43, -68a, -87,
-90, -91, and -114). In cervicovaginal samples with multiple HPV types, the average
depth of coverage varied greatly from as low as 27 to 129,998 (Table 2), probably a
result of varying viral loads.
While some LA types were not detected by WGS in this small sample set (HPV26, -35,
-53, -72, -81, and -84), other LA types were detected in some but not all samples (HPV18
and -66). In some instances, eWGS detected types but did not meet the criteria for
number of reads or depth of coverage. For example, in sample 25, eWGS failed to call
HPV66 and HPV18, which were detected by LA, but 1,478 reads mapped to HPV66 with
99% of the genome covered but failed because the average depth of coverage (18.9)
was just below the cutoff of 20. HPV18 had a subthreshold of 234 reads mapped with
71% genome coverage. In sample 20, eWGS failed to call HPV72; although 1,412 reads
mapped to HPV72 with 87% genome coverage, the average depth of coverage of 17.7
was below the cutoff of 20.
FIG 3 Mapping results showing high specificity of RNA baits restricted to the HPV18 genome integrated into the HeLa genome. The reduced fraction of HPV
genome, covered by the sequenced reads due to deletion of the central region of the HPV18 genome (the central region indicated within the two dashed
vertical lines), compatible with a deletion due to integration, is shown reproducibly with 100 ng (A) and 10 ng (B) input DNA. The stringent L1-S1 mapping
conditions result in small gaps in the consensus sequence due to mismatched reads. Mapping results schematically aligned to HPV genome with the location
of early and late region genes (C).
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TABLE 2 HPV genotype determination in blinded samples based on target enrichment and whole-genome sequencing
Sample
no.a Sample type
No. of reads
mapped Avg coverage
Fraction of genome
covered (>0.5)
HPV typeb
ConcordancecWGS result LA result
1 Plasmid 282,773 3,598.5 0.99 45 45 Yes
2 Plasmid 293,528 3,751.6 1.00 58 58 Yes
3 Plasmid 210,381 2,659.0 1.00 31 31 Yes
4 Plasmid 190,903 2,413.7 0.99 33 33 Yes
5 Plasmid 237,806 2,994.3 1.00 52 52 Yes
6 Plasmid 268,460 3,357.4 1.00 6 6 Yes
7 Plasmid 95,100 1,210.4 1.00 18 18 Yes
8 Plasmid 169,355 2,135.4 1.00 11 11 Yes
17d Cervicovaginal 16,120 208.7 0.16 34 Yes, partial
1,736 379 0.85 64 (34 subtype) 64 (reclassified as
34 subtype)
81
18 Cervicovaginal 7,873 100.9 0.99 67 67 Yes
10,820 139.5 0.97 54 54
8,012 101.4 0.91 70 70
3,967 49.4 0.99 90*
19 Cervicovaginal 667,344 8,554.6 0.90 67 67 Yes
675,774 8,535.7 0.97 42 42
680,615 8,425.5 0.91 89 89
345,249 4,372.5 0.82 59 59
170,609 2,105.2 0.53 83 83
36,981 472.7 1.00 66 66
32,800 419.2 0.72 58 58
13,844 176.5 0.91 56 56
20 Cervicovaginal HPV 72, 35, 52, 53, 54,
62, 81
No
21 Cervicovaginal HPV HPV Yes
22 Cervicovaginal HPV 6, 53, 56, 62, 70 No
23 Cervicovaginal 135,138 1,711.5 0.73 59 59 Yes, partial
110,107 1,392.2 0.99 40 40
95,442 1,193.2 0.99 87*
73,386 940.7 0.84 67 67
49,125 638.0 0.87 73 73
36,101 452.7 0.98 43*
29,721 375.9 0.97 16 16
13,891 171.4 0.73 83 83
9,380 119.9 0.99 66 66
3,091 39.5 0.99 68a*
2,121 27.0 0.85 56 56
45, 51, 61, 89
24 Cervicovaginal 2503,879 31,916.9 0.99 56 56 Yes, partial
2221,727 27,974.4 1.00 52 52
1054,024 13,048.1 0.99 89 89
598,662 7,506.7 0.90 43*
266,588 3,318.7 0.98 90*
213,130 2,692.1 0.95 42 42
50,171 628 0.66 61 61
40,905 523.9 0.99 51 51
31,221 390.3 0.98 87*
53, 68b
25 Cervicovaginal HPV 66, 18, 31 No
26 Cervicovaginal 10277,696 129,998.7 1.00 16 16 Yes, partial
428,009 5,411.7 0.97 40 40
184,266 2,310.5 0.86 43*
127,862 1,609.9 0.99 52 52
118,695 1,490.0 0.83 91*
90,888 1,148.0 0.99 42 42
3,722 46.0 0.66 62 62
2,610 33.3 0.96 39 39
72, 83
27 Cervicovaginal HPV 26, 42, 58, 83, 84 No
28 Cervicovaginal 9,041 115.1 0.99 30* 35, 53 No
29 Cervicovaginal 23,813 295.1 0.76 114* 40, 54, 66, 84, 89 No
(Continued on next page)
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In sample 29, LA detected HPV84 but eWGS detected HPV114. HPV84 and HPV114
have 84% identity over the whole genome, suggesting the possibility of misclassifica-
tion based on genomic fragments. To explore this, sample 29 reads were mapped with
HPV84 as the only reference sequence. While no reads mapped to HPV84 under
stringent conditions, under L0.5-S0.8 conditions 62,203 reads mapped to HPV84 with
94% of the genome covered. HPV53 was not identified in any of the 4 samples that
were LA positive for this type; however, HPV53 sequences were found in one of four
samples (number of reads, 1,438; average coverage, 18; genome coverage, 99%) if
mapping was done under less stringent conditions (L0.5-S0.8).
LA includes probes for HPV64, which has been reclassified as a subtype of HPV34.
For sample 17, 16,120 reads mapped to HPV34 with 16% coverage (compared to the
whole genome), whereas 1,736 reads mapped to a 458-bp HPV64 L1 partial sequence
(GenBank accession number AJ812226.1) with 85% coverage. As the full-length refer-
ence sequence for HPV64 is not available and HPV64 has been reclassified as a subtype
of HPV34, the eWGS results were assigned to HPV64 based on post hoc assessment,
giving partial concordance with LA results.
Evaluation of custom HPV bait. The performance of the HPV custom RNA bait pool
for the 9 HPV types included as individual plasmids is shown in Table 3. One HPV6 bait
sequence had to be removed due to homology with the human genome, resulting in
TABLE 2 (Continued)
Sample
no.a Sample type
No. of reads
mapped Avg coverage
Fraction of genome
covered (>0.5)
HPV typeb
ConcordancecWGS result LA result
30 Cervicovaginal 2102,063 26,836.0 1.00 39 39 Yes
1743,872 22,288.8 0.99 66 66
81,139 1,039.2 0.85 51 51
49,403 617.8 0.62 6 6
12,102 152.6 0.96 11 11
31 Cervicovaginal HPV HPV Yes
32 Plasmid 270,183 3,417.4 1.00 16 16 Yes
aSample numbers 1 to 8 were multiplexed with control samples in pool 1, and samples 17 to 32 were multiplexed in pool 2. Sequence information is given only for
those that passed the signal/noise cutoff for HPV type determination.
bAsterisks indicate HPV types not included in LA but detected by WGS. Boldface indicates types detected by both assays, while italics indicates types not included in
LA assay.
cHPV concordance based on WGS and LA results.
dHPV64 has been reclassified as a subtype of HPV34. The only reference sequence available for HPV64 is an L1 fragment. On post hoc assessment, results for this
sample are assigned to HPV64 based on reads mapped to the L1 fragment with good coverage and reads mapping to HPV34 with low genome coverage.
TABLE 3 Performance of different RNA bait evaluation metrics based on WGS mapping
results under L1-S1 from plasmid samples
Sample
no.
HPV typea
(eWGS result)
Bait design
coverageb (%)
HPV genome
coverage by
mapped
readsc (%)
HPV reads
mapped to
predicted
typed (%)
Uniformity of
coveragee (%)
1 45 100 99.0 99.8 96.3
2 58 100 100 99.7 96.3
3 31 100 100 99.7 96.3
4 33 100 99.2 99.2 96.3
5 52 100 100 99.7 96.3
6 6 99.2 100 99.8 96.3
7 18 100 100 100 96.3
8 11 100 100 99.5 92.6
32 16 100 100 99.8 96.3
Mean 99.9 99.8 99.6 95.9
aHPV type determined by eWGS for the corresponding sample numbers (Table 2).
bProportion of the HPV genome covered by the bait design criteria.
cProportion of the HPV reference genome covered by the mapped reads.
dProportion of reads that mapped to HPV predicted type compared to the total HPV reads.
eUniformity of coverage across the genome was calculated as the percentage of bins with coverage within
the average read depth  2 SD for all bins (see Materials and Methods for details).
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99.2% design coverage for that type; design coverage was 100% for the other 8 types.
The mean coverage of mapped reads to reference sequences was 99.8% (range, 99.2 to
100%), and 99.2 to 100% of HPV reads mapped to the predicted type (mean, 99.60%).
The mapped reads gave 95.9% uniform mean coverage (range, 92.6 to 96.3%), sug-
gesting that the bait resulted in unbiased enrichment of the whole HPV genome. The
eWGS method averaged 184,483-fold enrichment for HPV sequences in HPV-positive
samples (range, 3,294 to 914,377).
DISCUSSION
This is the first application of NGS for whole-genome identification of essentially all
known HPV types (191 HPV types in the alpha, beta, and gamma genera) using RNA
baits of the Agilent SureSelect target enrichment technology. The target enrichment
method avoids the limitations of targeting only limited areas of the genome, minimizes
the potential for PCR bias, and significantly increases the potential to increase the
number of types identified in a single assay. A recent report using Roche NimbleGen
DNA bait-based target enrichment largely focused on understanding the mechanistic
signatures of integration of HPV types (87 types, 63% alpha) in cervical carcinomas
(17), with limited data on NGS-based HPV type determination and concordance
with a current HPV typing assay. In comparison, we mainly focused on the devel-
opment of a universal HPV typing assay to detect all known HPV types in epide-
miologic studies that increasingly examines a broad spectrum of HPV in alpha, beta,
and gamma genera in both mucosal and cutaneous specimens for their disease
association (5, 6, 11, 22). Toward this goal, we evaluated our method in terms of the
performance of RNA baits for whole-genome identification, level of enrichment, and
a number of read-mapping metrics for determination of HPV types under single and
multiple infection.
The custom RNA bait library exhibited excellent performance in terms of the
fraction of genome coverage, percentage of on-target reads mapped to predicted
HPV types, uniformity of coverage for the types that we evaluated, and an observed
average level of target enrichment (184,483) by a factor of nearly 5 log. Our results
support the concept of specific capture and whole-genome sequencing of viruses
from clinical samples through target enrichment technologies (18, 23, 24). Sequenc-
ing the target enriched libraries generated high-quality reads with more than 88%
of bases having Q scores greater than 30. Mapping results revealed that this
method could detect single and multiple infections of HPV along with HBG as an
internal control for cellularity.
The mapping stringencies and threshold for the number of mapped reads required
to avoid bleed-through of nonspecific HPV signals was established using 8 control
samples (3 cell line controls at 100 ng, 3 cell line controls at 10 ng, human placental
DNA at 100 ng, and water at 0 ng). The most stringent L1-S1 mapping conditions, along
with a cutoff of 1,000 mapped reads, average coverage of 20, and fraction of
genome covered of greater than 50%, allowed reliable sequence assignment. The
control cell lines, Caski (500 HPV16 copies/cell), HeLa (50 HPV 18 copies/cell), and
SiHa (1 to 2 HPV16 copies/cell), vary in copy numbers of HPV and were analyzed at two
concentrations of input DNA (100 ng and 10 ng in 50 l). In each case, the number of
mapped reads under stringent conditions roughly correlated with copy number, and
type assignment could be made with an input of 10 ng DNA. In agreement with
previous reports using other methods (25, 26), the fraction of genome covered for
HPV18 in HeLa cells was only 63%, since no reads mapped to a 2.6-kbp central region
(nt 3100 to 5730), compatible with a deletion due to integration.
The bleed-through of reads from dominant sequences in adjacent clusters has been
reported in multiplexed samples sequenced using the Illumina platform (27, 28). This
might happen more frequently under relatively high seeding density for cluster gen-
eration and when one sequence dominates. These two conditions seemed to have
taken place in this study. At the seeding density of 5.3 pM used in this study, pool 1 and
pool 2 libraries generated cluster densities of 1,173,000 and 1,183,000, respectively,
Li et al. Journal of Clinical Microbiology
March 2017 Volume 55 Issue 3 jcm.asm.org 818
which is slightly higher than the recommended cluster density of 850,000 to 1,000,000.
Additionally, over 31 million reads of HPV16 from Caski (100 ng) dominated sequences
and corresponded to the HPV16 bleed-through found in other samples in the same
pool. The HPV16 sequences in the placental DNA negative control in pool 1 had the
unique 29 nucleotide substitutions identical to Caski HPV16 sequences (data not
shown). It is unlikely that misidentification of barcode sequences contributed to
bleed-through, since we restricted the analysis to reads with 0 mismatches in the index
reads.
We applied the mapping stringency and cutoff determined with the control samples
for determination of HPV types in 24 samples blinded to their HPV status. The HPV
types determined by the eWGS were 100% concordant with LA in the 9 plasmid
samples, but concordance was lower in the cervicovaginal samples (Table 2). Nine of 15
samples (60%) showed complete or partial concordance, and type-specific concordance
for the 37 LA types was 95.83%. It could be anticipated that biologic samples from
exfoliated cells would present greater challenges to HPV detection than purified
plasmid DNA. These samples vary significantly in the amount of cellular and viral
material. Given the relationship between viral copy number and number of reads noted
in the plasmid and cell line results, it could be suspected that low copy numbers
contribute to failure to detect types found by LA. Additionally, LA used 10 l of extract
regardless of the DNA concentration, while the eWGS method used 100 ng. Of the 4
samples that were LA positive but eWGS negative, three had 6 to 10 times (600 to 1,030
ng) more DNA input for LA. On the other hand, even with only 15 epidemiologic
samples, eWGS detected 7 HPV types (HPV30, -43, -68a, -87, -90, -91, and -114) not
targeted by LA. The ability of this eWGS method to detect HPV types not targeted by
current assays indicates it could be useful in evaluation of HPV-negative cervical lesions
(29) and in epidemiologic studies of HPV in geographic regions that may have uncom-
mon types in circulation (30).
Some HPV types detected by LA were not detected by eWGS in this small sample set
(HPV26, -35, -53, -72, -81, and -84). HPV84 was also reported as discordant between NGS
and LA in earlier studies (10, 15). Further evaluation is needed to determine explana-
tions for the failure to detect these types. Reduced mapping stringency did detect
HPV53 and HPV84 in some instances and there could be unreported variants affecting
mapping, and/or these types may be present at low copy numbers. We were able to
confirm the specificity of RNA baits for HPV53 at the highest stringency of reference
mapping by detecting HPV53 plasmid DNA (data not shown).
In conclusion, we developed and provided results from the initial evaluation of a
non-PCR whole-genome sequence-based approach which is possibly close to a gold
standard for broad-spectrum HPV genotype determination. The method relies on a
custom-made RNA bait library that showed excellent performance in terms of genome
coverage, percentage of reads mapped to predicted HPV type, uniformity of coverage,
and the level of target enrichment. Further optimization and evaluation of this eWGS
method for HPV detection is required in terms of cost per sample and throughput.
Additional studies with samples including more types and optimization of sequencing
conditions to minimize the bleed-through are needed. Studies evaluating the repro-
ducibility and lower limits of detection are planned. Finally, it should be noted that
despite enrichment with RNA bait by a factor of 5 log, 75% of the total reads (average)
were human (off-target), with the exception of the sample with the highest viral load
(100 ng Caski), in which 36% of total reads were off-target (data not shown). This
suggests adjustment in the conditions for on-target enrichment could enhance results.
Future laboratory and bioinformatics efforts are focused on determining the sensitivity
and reproducibility of this HPV genotyping method, along with expanding its applica-
tion for HPV detection and genotyping in samples from a variety of anatomical sites
and development of a bioinformatics pipeline for automatic determination of HPV
types and variants. This methodology is conceptually suitable for detecting both known
and unknown HPV types through adjusting stringencies at the level of hybridization to
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RNA bait and reference mapping parameters. The current reference mapping strin-
gency used to detect known HPV genotypes would likely miss unknown types.
MATERIALS AND METHODS
Samples. DNA extracted from three cells lines (ATCC, Manassas, VA) known to include HPV16 (Caski,
500 copies/cell; SiHa, 1 to 2 copies/cell) and HPV18 (HeLa; 50 copies/cell) served as HPV-positive
controls, and water and human placental DNA (Sigma-Aldrich Corporation, St. Louis, MO) were included
as HPV-negative controls. A panel of coded samples was prepared so that testing and analysis could be
performed in a blinded fashion. The blinded set included 9 residual samples from past WHO validation
panels (whole HPV genome DNA plasmids diluted to 50,000 copies/sample in human placental DNA [100
ng/50 l]) and 15 residual DNA extracts from anonymized cervical/vaginal samples previously typed
using the Linear Array (LA; Roche Molecular Diagnostics, Indianapolis, IN). Two of the cervical/vaginal
extracts were negative for the 37 genotypes targeted by LA, and the other 13 samples were selected to
include multiple HPV genotypes (median, 5; range, 2 to 12). DNA was quantified by fluorescence-based
PicoGreen assay (Molecular Probes, Inc., Eugene, OR), and volume was adjusted with a buffer (pH 8.0)
composed of 10 mM Tris-HCl and 1 mM EDTA so that a final concentration of 100 ng/50 l was used for
library preparation. The exception was the water blank (0 ng DNA) and cell line samples that were also
prepared at 10 ng DNA to test the effect of reduced DNA input on sequencing results. The final number
of samples sequenced was 32: 8 control samples (3 cell line controls at 100 ng, 3 cell line controls at 10
ng, human placental DNA at 100 ng, and water at 0 ng) and 24 blinded samples (9 plasmid samples and
15 cervical/vaginal extracts [100 ng]).
HPV whole-genome reference sequences. We retrieved the whole-genome HPV reference se-
quences for all 188 HPV genotypes that were available in the PapillomaVirus Episteme (PaVE) database
(http://pave.niaid.nih.gov/) as of September 2014 (31). We also retrieved whole-genome sequences for
three HPV subtypes detected by LA (HPV55 [an HPV44 subtype], HPV82A/IS39, and HPV68b) from the
National Center for Biotechnology (NCBI) database (http://www.ncbi.nlm.nih.gov/). The 191 HPV refer-
ence genomes included in this study (see Table S1 in the supplemental material) ranged in size from
7,095 to 8,104 bp and were distributed phylogenetically into 5 genera (67 alpha, 47 beta, 74 gamma, 2
mu, and 1 nu). The complete reference sequences were used for RNA bait design as well as for sequence
mapping.
Design and synthesis of RNA baits. Agilent Technologies Inc. (Santa Clara, CA) designed a custom
RNA bait library, using eArray software, comprised of 120-base RNAs complementary to one strand of the
whole genomes of all 191 HPV genotypes at 2-fold coverage (60 bases overlapping). The resulting 23,941
RNA sequences comprised a bait library size of 1.442 Mbp. The bait library sequences were subjected to
BLAST (Basic Local Alignment Search Tool) search against the NCBI human genome database, and 21
fragments were identified to have homology to human sequences. Removing these 21 fragments from
RNA bait synthesis resulted in 100% coverage for 182 HPV genotypes and 99.17% to 99.25% coverage
for 9 HPV genotypes (HPV6, -19, -34, -71, -82A/IS39, -142, -171, -172, and -175), for an overall design
coverage of 99.96%. A BLAST search of the final synthesized bait sequences against the full NCBI
database identified 15,669 unique hits, with 99.94% being specific to HPV sequences. The other 10 hits
(0.064%) shared identity to chimpanzee, feline, and macaque papillomaviruses. As an internal control for
the quality of samples, we included 12 RNA fragments covering nt 2041 to 3480 of the coding sequence
of the human beta-globin (HBG) gene (1,439 bp; GenBank accession number GU324922.1). The custom
biotinylated RNA bait library (HPV and HBG) was synthesized at Agilent Technologies. Upon request to
the authors, the custom-designed ID may be shared with those who want to synthesize these probes
through Agilent Technologies.
Target enrichment library preparation and sequencing. The workflow for the preparation of the
sequencing library followed Agilent Technologies’ SureSelectXT2 target enrichment protocol (version D3),
optimized for 100 ng DNA (Fig. 4). Briefly, DNA samples (50 l in a 96-well microTUBE plate) were sheared
using a Covaris LE220 focused ultrasonicator with SonoLab 7.3.2.4 software (Covaris, Inc., Woburn, MA).
The conditions used for shearing (duty factor, 15%; peak incident power, 450; treatment time, 490 s)
generated DNA fragments with a peak around 150 bp as determined by the high-sensitivity DNA kit and
a Bioanalyzer 2100 (Agilent Technologies). DNA fragments were end repaired and 3= A-tailed, and they
underwent precapture indexing whereby each sample was barcoded with an index of 8 bp sequence.
Indexed libraries were amplified by PCR with a limited number of cycles (8 cycles), followed by
purification and assessment of the quality and quantity of each library by a Bioanalyzer 2100 (Agilent
Technologies). Indexed libraries with unique barcodes were pooled (16 samples/pool) for overnight
hybridization with custom RNA bait, followed by capture of hybridized fragments and 14 cycles of PCR
to amplify indexed libraries. Following further purification, the quality and quantity of postcapture
HPV enriched pooled libraries were assessed by a Bioanalyzer 2100 and quantitative PCR (qPCR)
using a KAPA DNA library quantification kit (KAPA Biosystems, Wilmington, MA) and a LightCycler
480 (Roche Diagnostics, Indianapolis, IN). Pooled libraries were paired-end sequenced on a two-lane
flow cell on Illumina HiSeq 2500 at the Centers for Disease Control and Prevention (CDC) Core
Facility using TruSeq Rapid SBS kit HS (200 cycle) (Illumina, San Diego, CA) with Rapid run mode
according to the following settings: read 1, 100 cycles; index (i7), 9 cycles; read 2, 100 cycles. For
each DNA library, a seeding concentration of 5.33 pM was applied for cluster generation, with 5%
PhiX virus genome library added as a sequencing control.
Bioinformatics. The raw sequence data were demultiplexed, and the adaptors and barcodes were
removed using Illumina BCl2fastq V1.8.4. Reads with a base Q score were exported as fastq files for batch
mapping to reference sequences using CLC Genomics Workbench 7.5 (CLC bio, Waltham, MA). The
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reference sequences of 191 HPV types/subtypes and HBG that were used for bait design were imported
into CLC Genomics Workbench for mapping.
The analysis was directed to HPV detection and typing, so duplicate reads were not removed. We
used reads with 0 mismatches in the index sequence for analysis in this report. Two parameters, read
lengths (L0.5 or L1) and similarity scores (S0.8 or S1.0), were used to adjust mapping stringency. BAM
(binary alignment/map) files were analyzed to generate mapping statistics by CLC Genomics Workbench.
Three additional parameters were evaluated in the process of differentiating signal from noise: number
of reads mapped to the HPV type-specific reference sequence, average depth of coverage for the
mapped sequences, and fraction of HPV genome covered by mapped reads. HPV types in 8 control
samples detected by eWGS with different mapping stringency and acceptance parameters were re-
corded prior to unblinding expected HPV results from 24 blinded samples. Subsequent matching of HPV
genotype calls by WGS to expected results was used to evaluate performance of the assay and analysis.
RNA bait performance was evaluated based on results from single HPV plasmids: percentage of HPV
reference genome covered by sequenced reads, percentage of reads that mapped to predicted types
(compared to total HPV reads), and uniformity of coverage. To evaluate the uniformity, the reference
sequences were divided into bins consisting of 300 bp, and the average mapping depth within each bin
was calculated by Strand NGS software (http://www.strand-ngs.com/) using BAM files generated by CLC
Genomics Workbench under L1-S1 mapping stringency. The mean and the standard deviation (SD) of the
average mapping depths among the bins were calculated. The uniformity of coverage was calculated as
the percentage of bins with coverage within the average read depth  2 SD for all bins. The target
enrichment factor for a sample was calculated using the following formula: (total HPV mapped reads/
total HPV and human mapped reads)/(HPV genome size/human diploid genome size) (32). HPV and
human diploid genome sizes were considered to be 8 kbp and 6.6 Gbp, respectively, for this calculation.
SUPPLEMENTAL MATERIAL
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